After excluding 72 patients for whom IHC-based HR status was unavailable, there were 239 patients (41.3%) with HR-positive/HER2-negative (HR+/HER2-) breast cancer, 188 patients (32.5%) with HER2-positive breast cancer, and 151 patients (26.1%) with TNBC. This evidence concerns the gene ERBB2 and breast cancer.